Ustekinumab for the treatment of psoriasis: an evidence update

Zenas Zn Yiu; Richard B Warren

doi:10.12788/j.sder.2018.040

Ustekinumab for the treatment of psoriasis: an evidence update

Division of Musculoskeletal & Dermatological Sciences (L5)

Hope Hospital Salford Royal NHS Foundation Trust

Research output: Contribution to journal › Article › peer-review

482 Downloads (Pure)

Abstract

Ustekinumab is an interleukin-12/23 inhibitor used for the treatment of moderate-to-severe psoriasis. Here, we review new evidence since ustekinumab was licensed for relative efficacy in comparison with other biologic therapies from head-to-head randomized controlled trials and network meta-analyses for the treatment of psoriasis. We also review observational data emerging from psoriasis registries reporting the effectiveness and safety of ustekinumab. Overall, new evidence suggests that ustekinumab has a favorable balance between efficacy/effectiveness, safety, and tolerability and should remain a first-line biologic therapy option for patients with severe psoriasis at present.

Original language	English
Pages (from-to)	143-147
Number of pages	5
Journal	Seminars in Cutaneous Medicine and Surgery
Volume	37
Issue number	3
DOIs	https://doi.org/10.12788/j.sder.2018.040
Publication status	Published - Sept 2018

Access to Document

10.12788/j.sder.2018.040

v37i3 WARREN_TO AUTHOR_ZYAccepted author manuscript, 116 KB

Risk and Predictors of Infections in Psoriasis Patients Exposed to Biologic Therapy: A Prospective Observational Cohort Study in the British Association of Dermatologists' Biologic Interventions Register (BADBIR).
Yiu, Z. (PI), Ashcroft, D. (CoI), Griffiths, C. (CoI) & Warren, R. (CoI)
1/10/15 → 30/09/18
Project: Research

Cite this

@article{2c6b0b2e60964581b446092851b7b049,

title = "Ustekinumab for the treatment of psoriasis: an evidence update",

abstract = "Ustekinumab is an interleukin-12/23 inhibitor used for the treatment of moderate-to-severe psoriasis. Here, we review new evidence since ustekinumab was licensed for relative efficacy in comparison with other biologic therapies from head-to-head randomized controlled trials and network meta-analyses for the treatment of psoriasis. We also review observational data emerging from psoriasis registries reporting the effectiveness and safety of ustekinumab. Overall, new evidence suggests that ustekinumab has a favorable balance between efficacy/effectiveness, safety, and tolerability and should remain a first-line biologic therapy option for patients with severe psoriasis at present.",

author = "Yiu, \{Zenas Zn\} and Warren, \{Richard B\}",

note = "{\textcopyright}2018 Frontline Medical Communications.",

year = "2018",

month = sep,

doi = "10.12788/j.sder.2018.040",

language = "English",

volume = "37",

pages = "143--147",

journal = "Seminars in Cutaneous Medicine and Surgery",

issn = "1085-5629",

publisher = "Frontline Medical Communications Inc.",

number = "3",

}

TY - JOUR

T1 - Ustekinumab for the treatment of psoriasis

T2 - an evidence update

AU - Yiu, Zenas Zn

AU - Warren, Richard B

PY - 2018/9

Y1 - 2018/9

N2 - Ustekinumab is an interleukin-12/23 inhibitor used for the treatment of moderate-to-severe psoriasis. Here, we review new evidence since ustekinumab was licensed for relative efficacy in comparison with other biologic therapies from head-to-head randomized controlled trials and network meta-analyses for the treatment of psoriasis. We also review observational data emerging from psoriasis registries reporting the effectiveness and safety of ustekinumab. Overall, new evidence suggests that ustekinumab has a favorable balance between efficacy/effectiveness, safety, and tolerability and should remain a first-line biologic therapy option for patients with severe psoriasis at present.

AB - Ustekinumab is an interleukin-12/23 inhibitor used for the treatment of moderate-to-severe psoriasis. Here, we review new evidence since ustekinumab was licensed for relative efficacy in comparison with other biologic therapies from head-to-head randomized controlled trials and network meta-analyses for the treatment of psoriasis. We also review observational data emerging from psoriasis registries reporting the effectiveness and safety of ustekinumab. Overall, new evidence suggests that ustekinumab has a favorable balance between efficacy/effectiveness, safety, and tolerability and should remain a first-line biologic therapy option for patients with severe psoriasis at present.

U2 - 10.12788/j.sder.2018.040

DO - 10.12788/j.sder.2018.040

M3 - Article

C2 - 30215630

SN - 1085-5629

VL - 37

SP - 143

EP - 147

JO - Seminars in Cutaneous Medicine and Surgery

JF - Seminars in Cutaneous Medicine and Surgery

IS - 3

ER -

Ustekinumab for the treatment of psoriasis: an evidence update

Abstract

Access to Document

Fingerprint

Projects

Risk and Predictors of Infections in Psoriasis Patients Exposed to Biologic Therapy: A Prospective Observational Cohort Study in the British Association of Dermatologists' Biologic Interventions Register (BADBIR).

Cite this